ALLIANCES (Sanofi) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended				12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2013 Avapro Avalide [Member]	Dec. 31, 2012 Avapro Avalide [Member]	Dec. 31, 2011 Avapro Avalide [Member]	Dec. 31, 2013 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Dec. 31, 2012 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Dec. 31, 2011 Sanofi [Member] Avapro Avalide [Member] Active Pharmaceutical Ingredient Supply Arrangements [Member]	Dec. 31, 2018 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2013 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2011 Sanofi [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Avalide [Member] Avalide supply disruption [Member]	Dec. 31, 2013 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2011 Sanofi [Member] Territory Covering Americas and Australia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2011 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member]	Dec. 31, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Discovery Royalties [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Discovery Royalties [Member]	Dec. 31, 2011 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Discovery Royalties [Member]	Dec. 31, 2013 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Receivables And Payables Net Cash Distributions Intercompany Balances [Member]	Dec. 31, 2012 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Receivables And Payables Net Cash Distributions Intercompany Balances [Member]	Dec. 31, 2011 Sanofi [Member] Territory Covering Europe and Asia [Member] Avapro, Avalide, and Plavix [Member] Receivables And Payables Net Cash Distributions Intercompany Balances [Member]
Alliances Statement [Line Items]
Payment from Sanofi related to restructuring of the alliance agreement																			$ 200
Controlling interest ownership percentage																								50.10%			50.10%
Noncontrolling interest ownership percentage																								49.90%			49.90%
Net product sales									12,304	13,654	17,622									153	2,930	8,003
Royalty revenue																								220
Development and opt-out royalty income																									143	126
Development royalty expense																									67	182
Previously deferred profit recognized upon restructuring of an alliance agreement																											22
Alliance and other revenues									4,081	3,967	3,622					116	117	33		336	120	37
Total Revenues	4,441	4,065	4,048	3,831	4,191	3,736	4,443	5,251	16,385	17,621	21,244		231	503	952					489	3,050	8,040
Cost of products sold - Cost of product supply																				4	81	245
Cost of products sold - Royalties																				4	530	1,583
Equity in net income of affiliates									(166)	(183)	(281)																(183)	(201)	(298)
Other (income)/expense									205	(80)	(334)									(18)	(171)	72	80
Noncontrolling interest - pre-tax																				36	844	2,323
Distribution (to)/from Sanofi - Noncontrolling interest									(29)	740	2,354													43	(742)	(2,335)
Distributions from Sanofi - Noncontrolling interest																											149	229	283
Investment in affiliates																											43	9
Noncontrolling interest	82				15				82	15	(89)	(75)												49	(30)
Net sales																											395	1,077	1,469
Gross profit																											319	453	658
Net income																											313	394	562
Cost of products sold																														38	133	184
Current assets and current liabilities																																	$ 108	$ 293	$ 400